These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 35326407)
1. Polymorphism of Baculoviral Inhibitor of Apoptosis Repeat-Containing 5 (BIRC5) Can Be Associated with Clinical Outcome of Non-Small Cell Lung Cancer. Szczyrek M; Mlak R; Szudy-Szczyrek A; Wojas-Krawczyk K; Kędziora K; Milanowski J Cells; 2022 Mar; 11(6):. PubMed ID: 35326407 [TBL] [Abstract][Full Text] [Related]
2. Genetic variation in a miR-335 binding site in BIRC5 alters susceptibility to lung cancer in Chinese Han populations. Zu Y; Ban J; Xia Z; Wang J; Cai Y; Ping W; Sun W Biochem Biophys Res Commun; 2013 Jan; 430(2):529-34. PubMed ID: 23232114 [TBL] [Abstract][Full Text] [Related]
3. BIRC5 promoter SNPs do not affect nuclear survivin expression and survival of malignant pleural mesothelioma patients. Hmeljak J; Erčulj N; Dolžan V; Kern I; Cör A J Cancer Res Clin Oncol; 2011 Nov; 137(11):1641-51. PubMed ID: 21861135 [TBL] [Abstract][Full Text] [Related]
4. Influence of survivin (BIRC5) and caspase-9 (CASP9) functional polymorphisms in renal cell carcinoma development: a study in a southern European population. Marques I; Teixeira AL; Ferreira M; Assis J; Lobo F; Maurício J; Medeiros R Mol Biol Rep; 2013 Aug; 40(8):4819-26. PubMed ID: 23645041 [TBL] [Abstract][Full Text] [Related]
5. Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer--a pilot study. Krawczyk P; Wojas-Krawczyk K; Mlak R; Kucharczyk T; Biernacka B; Milanowski J Folia Histochem Cytobiol; 2012 Apr; 50(1):80-6. PubMed ID: 22532140 [TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy. Lee SY; Kang HG; Yoo SS; Kang YR; Choi YY; Lee WK; Choi JE; Jeon HS; Shin KM; Oh IJ; Kim KS; Lee J; Cha SI; Kim CH; Kim YC; Park JY Lung Cancer; 2013 Nov; 82(2):330-9. PubMed ID: 23973201 [TBL] [Abstract][Full Text] [Related]
7. The effect of polymorphisms in the promoter of the BIRC5 gene on the risk of oesophageal squamous cell carcinoma and patient's outcomes. Wang N; Li Y; Zhou RM; Cui SJ; Cao SR; Huang X; Huo XR; Shan BE Mutagenesis; 2019 Dec; 34(4):307-313. PubMed ID: 31165868 [TBL] [Abstract][Full Text] [Related]
8. A candidate single nucleotide polymorphism in the 3' untranslated region (rs17878624) of survivin gene for NSCLC. Aynaci E; Coskunpinar E; Yildiz P Cell Mol Biol (Noisy-le-grand); 2018 Mar; 64(4):119-122. PubMed ID: 29631694 [TBL] [Abstract][Full Text] [Related]
9. BIRC5: A novel therapeutic target for lung cancer stem cells and glioma stem cells. Kahm YJ; Kim RK Biochem Biophys Res Commun; 2023 Nov; 682():141-147. PubMed ID: 37806253 [TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of survivin polymorphisms on non-small cell lung cancer survival. Dai J; Jin G; Dong J; Chen Y; Xu L; Hu Z; Shen H J Thorac Oncol; 2010 Nov; 5(11):1748-54. PubMed ID: 20881643 [TBL] [Abstract][Full Text] [Related]
11. The impact of functional LIG4 polymorphism on platinum-based chemotherapy response and survival in non-small cell lung cancer. Jiang YH; Xu XL; Ruan HH; Xu WZ; Li D; Feng JG; Han QB; Mao WM Med Oncol; 2014 May; 31(5):959. PubMed ID: 24722796 [TBL] [Abstract][Full Text] [Related]
12. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer. Zhao W; Hu L; Xu J; Shen H; Hu Z; Ma H; Shu Y; Shao Y; Yin Y Cancer Chemother Pharmacol; 2013 May; 71(5):1287-95. PubMed ID: 23479135 [TBL] [Abstract][Full Text] [Related]
13. Role of survivin re-expression in the development and progression of non-small cell lung cancer. Javid J; Mir R; Julka PK; Ray PC; Saxena A Tumour Biol; 2015 Jul; 36(7):5543-50. PubMed ID: 25677909 [TBL] [Abstract][Full Text] [Related]
14. Predictive value of STMN1 gene promoter polymorphism (-2166T>C) in patients with advanced NSCLC treated with the combination of platinum compounds and vinorelbine. Mlak R; Krawczyk P; Ciesielka M; Homa I; Powrózek T; Prendecka M; Kozioł P; Milanowski J; Małecka-Massalska T Cancer Chemother Pharmacol; 2015 Sep; 76(3):621-9. PubMed ID: 26220844 [TBL] [Abstract][Full Text] [Related]
15. Association between survivin genetic polymorphisms and epidermal growth factor receptor mutation in non-small-cell lung cancer. Liu TC; Hsieh MJ; Wu WJ; Chou YE; Chiang WL; Yang SF; Su SC; Tsao TC Int J Med Sci; 2016; 13(12):929-935. PubMed ID: 27994498 [TBL] [Abstract][Full Text] [Related]
16. Survivin expression impacts prognostically on NSCLC but not SCLC. Rosato A; Menin C; Boldrin D; Dalla Santa S; Bonaldi L; Scaini MC; Del Bianco P; Zardo D; Fassan M; Cappellesso R; Fassina A Lung Cancer; 2013 Feb; 79(2):180-6. PubMed ID: 23218791 [TBL] [Abstract][Full Text] [Related]
17. Association of BIRC5 Gene Polymorphism with the Collateral Circulation and Severity of Large Artery Atherosclerotic Stroke. Huang J; Li X; Zhao J; Chen H; Yun Y; Yang G; Jiang Y; Pan Y; Yuan S; Huang J; Su L; Wu Y; Lu D; Xu A; Meng L Int J Clin Pract; 2022; 2022():9177545. PubMed ID: 35685607 [TBL] [Abstract][Full Text] [Related]
18. [Influence of genetic variation of programmed death-ligand 1 (PD-L1) on the prognosis of patients with non-small cell lung cancer who received platinum-based adjuvant chemotherapy]. Zhang GW; Cheng RR; Zhang FR; Li P; Chu HY; Song XJ; Zhang GJ Zhonghua Yi Xue Za Zhi; 2020 Sep; 100(34):2682-2688. PubMed ID: 32921017 [No Abstract] [Full Text] [Related]
19. Genetic variants of NBS1 predict clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer in Chinese. Xu JL; Hu LM; Huang MD; Zhao W; Yin YM; Hu ZB; Ma HX; Shen HB; Shu YQ Asian Pac J Cancer Prev; 2012; 13(3):851-6. PubMed ID: 22631660 [TBL] [Abstract][Full Text] [Related]
20. The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC. Wang YD; Ha MW; Cheng J; Zhang WL; Cong X; Tong CY; Sun J Oncol Rep; 2012 Apr; 27(4):979-86. PubMed ID: 22179630 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]